In TNBC, the expression of TIGIT was shown on immune cells in TME and CD155 on tumor cells concomitantly with PD-1 and PD-L1 expression on immune and tumor cells, respectively [216], thus indicating the potential of therapeutic targeting of TIGIT in TNBC. This evidence concerns the gene CD274 and neoplasm.